◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Net Income 2022–2026

Name: GlaxoSmithKline Pharmaceuticals Limited (GLAXO) net income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

GlaxoSmithKline Pharmaceuticals Limited annual net income for fiscal 2026 was ₹10.4 billion, an increase of 11.7% from ₹9.3 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

GLAXO Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	₹10.4B	₹9.3B	₹5.9B	₹6.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GLAXO Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Net Income	₹2.4B	₹2.8B	₹3.0B	₹2.1B	₹2.6B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4568 Net Income — Daiichi Sankyo Company, Limited
4503 Net Income — Astellas Pharma Inc.
4528 Net Income — Ono Pharmaceutical Co., Ltd.
4536 Net Income — Santen Pharmaceutical Co., Ltd.
RUBICON Net Income — Rubicon Research Limited
NOVN Net Income — Novartis AG

More GLAXO metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All GLAXO financial statements → Interactive GLAXO charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.